- $53.70m
- $44.23m
- $1.12m
Brief: Renovorx Engages Oklahoma University (Ou) Health As First Clinical Site
Brief: RenovoRx Files New International Patent For Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
Brief: RenovoRx Q3 Net Income USD -1.421 Million
Brief: Renovorx Inc - On Oct 31, Co Received Formal Notice, The Staff Of The Nasdaq Had Granted The Co’S Request For Continued Listing On Nasdaq
Brief: Renovorx says Got Letter From Nasdaq That Co Was Not In Compliance With Minimum Stockholders Equity Requirement For Continued Listing
Brief: RenovoRx, Imugene Announce Collaboration To Deliver Oncolytic Virus Therapy
Australia's Imugene hits 1-1/2-month high on collaboration with RenovoRx
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
RenovoRx rises on positive data from pancreatic cancer therapy study
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx
RenovoRx rises on positive data from pancreatic cancer therapy study
Brief: Renovorx Announces New Positive Interim Late-Stage Data For Cancer Treatment
Brief: RenovoRx Appoints Margaret Tempero To Scientific Advisory Board
Brief: Renovorx Initiates Patient Enrollment At University Of Texas Southwestern Medical Center For Pivotal Phase Iii Tiger-Pac Clinical Trial
Brief: Renovorx Reports First Quarter 2023 Financial Results And Operational Highlights
Brief: RenovoRx Appoints Robert Spiegel To Board Of Directors
Brief: Renovorx Presenting Phase Iii Trial Interim Analysis Data At American Association For Cancer Research Annual Meeting In Florida
RenovoRx rises on positive late-stage trial data for pancreatic cancer therapy
Brief: RenovoRx Announces Positive New Data From Phase III Clinical Trial Interim Analysis